Inhancment of meropenem potency by methotrexate nanoparticles
Keywords:
MTX, MTX NPs, UV-Vis spectra analysis, AFM, SEM, FTIR, MEMAbstract
The MTX was converted to MTX nanoparticles by the modified method based on changing the pH gradually . For the first time MTX NPs+Meropenem complex were prepared and evaluated as a potential tool to overcome antimicrobial resistance and to improve pharmacokinetics of the drug, the results showed that the antibacterial activity of complex (MTX NPs plus MEM) has increased (from 1( µg/ml) to >0.5( µg/ml) for p1 , from 2( µg/ml) to 1( µg/ml) for p10 and from 8( µg/ml) to 4( µg/ml) for p48).
Downloads
References
Abbas HH & Flayyih MT.(2022) . Synthesis and characterization of methotrexate nanoparticles .International Journal of Health Sciences,
Abdelkader A, El-Mokhtar MA, Abdelkader O, Hamad MA, Elsabahy M, El-Gazayerly ON. Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model. Carbohydrate polymers. 2017 Oct 15;174:1041-50.
Al Baloushi AE. Characterization of Carbapenemase Producer Enterobacteriaceae Isolated in the United Arab Emirates.
Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert review of anti-infective therapy. 2011 Nov 1;9(11):1035-52.
Andrews JM. Determination of minimum inhibitory concentrations. Journal of antimicrobial Chemotherapy. 2001 Jul 1;48(suppl_1):5-16.
Arya SS, Sharma MM, Das RK, Rookes J, Cahill D, Lenka SK. Vanillin mediated green synthesis and application of gold nanoparticles for reversal of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates. Heliyon. 2019 Jul 1;5(7):e02021.
Cho JC, Zmarlicka MT, Shaeer KM, Pardo J. Meropenem/vaborbactam, the first carbapenem/β-lactamase inhibitor combination. Annals of Pharmacotherapy. 2018 Aug;52(8):769-79.
Eleftheriadou I, Giannousi K, Protonotariou E, Skoura L, Arsenakis M, Dendrinou-Samara C, Sivropoulou A. Cocktail of CuO, ZnO, or CuZn nanoparticles and antibiotics for combating multidrug-resistant Pseudomonas aeruginosa via efflux pump inhibition. ACS Applied Nano Materials. 2021 Aug 20;4(9):9799-810
Elsaesser A, Howard CV. Toxicology of nanoparticles. Advanced drug delivery reviews. 2012 Feb 1;64(2):129-37.
Jayaprakash J, Sankari D, Johnthomas P, Johnmilton D, Swaminathan C, Sathish M, Ganesh M. Antibacterial and anti bio film activities of novel antibiotic conjugated silver nanoparticles. Materials Today: Proceedings. 2022 Jan 1;49:2836-41.
Mamun MM, Sorinolu AJ, Munir M, Vejerano EP. Nanoantibiotics: functions and properties at the nanoscale to combat antibiotic resistance. Frontiers in chemistry. 2021 May 13;9:687660.
Najafi M, Moghaddam MN, Yousefi E. The effect of silver nanoparticles on pyocyanin production of Pseudomonas aeruginosa isolated from clinical specimens. Avicenna Journal of Medical Biotechnology. 2021 Apr;13(2):98.
oxide nanoparticles and various antibiotics combination against Pseudomonas aeruginosa clinically isolated bacterial strains. Saudi Journal of Biological Sciences. 2021 Jan 1;28(1):928-35.
Pålsson-McDermott EM, O’Neill LA. Targeting immunometabolism as an anti-inflammatory strategy. Cell research. 2020 Apr;30(4):300-14.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules. 2021 May 2;26(9):2671.
Vivas R, Barbosa AA, Dolabela SS, Jain S. Multidrug-resistant bacteria and alternative methods to control them: an overview. Microbial Drug Resistance. 2019 Jul 1;25(6):890-908.
Wang S, Gao Y, Jin Q, Ji J. Emerging antibacterial nanomedicine for enhanced antibiotic therapy. Biomaterials Science. 2020;8(24):6825-39.
Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202
Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PR, Walkty A, Denisuik A, Golden A, Gin AS. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018 Jan;78(1):65-98.
Zhu Y, Hao W, Wang X, Ouyang J, Deng X, Yu H, Wang Y. Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections. Medicinal Research Reviews. 2022 Jan 4.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
